Nyrada Inc

NYR

Company Profile

  • Business description

    Nyrada Inc is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. Its flagship candidate, Xolatryp, is being developed for applications in cardioprotection and neuroprotection. The company operates in one segment being research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical need and it operates in one geographical area being Australasia.

  • Contact

    180 George Street, Sydney Place
    Level 22/23, Salesforce Tower
    SydneyNSW2000
    AUS

    T: +61 294983390

    https://www.nyrada.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    Employees

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,965.0032.30-0.36%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,508.17245.67-1.03%
NASDAQ24,328.38181.38-0.74%
Nikkei 22559,530.34669.911.14%
NZX 50 Index14,305.791.17-0.01%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,849.6033.60-0.38%
SSE Composite Index3,584.5817.99-0.50%

Market Movers